Bile acids activate farnesoid X receptor (FXR) and G protein-coupled bile acid receptor-1 (aka Takeda G protein-coupled receptor-5 [TGR5]) to regulate bile acid metabolism and glucose and insulin sensitivity. FXR and TGR5 are coexpressed in the enteroendocrine L cells, but their roles in integrated regulation of metabolism are not completely understood. We reported recently that activation of FXR induces TGR5 to stimulate glucagon-like peptide-1 (GLP-1) secretion to improve insulin sensitivity and hepatic metabolism. In this study, we used the intestine-restricted FXR agonist fexaramine (FEX) to study the effect of activation of intestinal FXR on the gut microbiome, bile acid metabolism, and FXR and TGR5 signaling. The current study revealed that FEX markedly increased taurolithocholic acid, increased secretion of fibroblast growth factors 15 and 21 and GLP-1, improved insulin and glucose tolerance, and promoted white adipose tissue browning in mice. Analysis of 16S ribosomal RNA sequences of the gut microbiome identified the FEX-induced and lithocholic acid-producing bacteria Acetatifactor and Bacteroides. Antibiotic treatment completely reversed the FEX-induced metabolic phenotypes and inhibited taurolithocholic acid synthesis, adipose tissue browning, and liver bile acid synthesis gene expression but further increased intestinal FXR target gene expression. FEX treatment effectively improved lipid profiles, increased GLP-1 secretion, improved glucose and insulin tolerance, and promoted adipose tissue browning, while antibiotic treatment reversed the beneficial metabolic effects of FEX in obese and diabetic mice. Conclusion: This study uncovered a mechanism in which activation of intestinal FXR shaped the gut microbiota to activate TGR5/GLP-1 signaling to improve hepatic glucose and insulin sensitivity and increase adipose tissue browning; the gut microbiota plays a critical role in bile acid metabolism and signaling to regulate metabolic homeostasis in health and disease. (HEPATOLOGY 2018; 68:1574-1588 (1,2) Bile acid synthesis in the liver generates two primary bile acids, cholic acid and chenodeoxycholic (CDCA), in humans. (3) In mice, CDCA is converted to a-muricholic acid
B
ile acids are known to regulate lipid, glucose, and energy homeostasis through activation of farnesoid X receptor (FXR) and G proteincoupled bile acid receptor-1 (aka Takeda G-proteincoupled receptor 5 [TGR5]). (1, 2) Bile acid synthesis in the liver generates two primary bile acids, cholic acid and chenodeoxycholic (CDCA), in humans. (3) In mice, CDCA is converted to a-muricholic acid Abbreviations: ABX, antibiotics; ACC, acetyl coenzyme A-carboxylase; BSH, bile salt hydrolase; CDCA, chenodeoxycholic acid; CYP7A1, cholesterol 7a-hydroxylase; CYP8B1, sterol 12a-hydroxylase; DMSO, dimethyl sulfoxide; EC50, 50% effect concentration; eWAT, epididymal WAT; FEX, fexaramine; FGF, fibroblast growth factor; FXR, farnesoid X receptor; GLP-1, glucagon-like peptide-1; iWAT, inguinal WAT; LCA, lithocholic acid; MCA, muricholic acid; NAFLD, nonalcoholic fatty liver disease; Osta, organic solute transporter 1a; PBS, phosphate-buffered saline; Prdm16, PR domain containing-16; Shp, small heterodimer partner; Sult2, sulfotransferase 2; TCA, taurocholic acid; TCDCA, taurochenodeoxycholic acid; TGR5, Takeda G protein-coupled receptor 5; TLCA, taurolithocholic acid; Ta-MCA, tauro-a-muricholic acid; Tb-MCA, tauro-b-muricholic acid; Ucp-1, uncoupling protein-1; UDCA, ursodeoxycholic acid; WAT, white adipose tissue.
(MCA) and b-MCA. Bile acids are conjugated to the amino acids glycine and taurine for secretion into bile and released into the gastrointestinal system to aid in the absorption of dietary nutrients. In the intestine, gut bacteria bile salt hydrolase (BSH) deconjugates conjugated bile acids and bacterial 7a-dehydroxylases and 7b-dehydroxylases convert the primary bile acids cholic acid and CDCA to the secondary bile acids deoxycholic acid (DCA) and lithocholic acid (LCA), respectively. Bacteria also can isomerize the 7a-hydroxyl group in CDCA to the 7b-hydroxyl group in ursodeoxycholic acid (UDCA), which is soluble and nontoxic. Enterohepatic circulation of bile acids from the intestine to the liver activates FXR, which represses bile acid synthesis through inhibition of cholesterol 7a-hydroxylase (Cyp7a1) and sterol 12a-hydroxylase (Cyp8b1) expression. In the intestine, FXR induces fibroblast growth factor 15 (FGF15), which activates hepatic FGF receptor 4 signaling in the liver to further inhibit Cyp7a1 transcription. (4) However, under physiological concentrations, taurocholic acid (TCA) may not be able to activate FXR in mouse liver (50% effect concentration [EC50] 5 0.6 mM), while taurochenodeoxycholic acid (TCDCA; EC50 5 17 lM) is the most potent endogenous FXR agonist and tauro-b-MCA (T-b-MCA; 50% inhibitory concentration 5 40 lM) is an FXR antagonist.
Activation of FXR is thought to be beneficial in improving insulin and glucose sensitivity in diabetes and nonalcoholic fatty liver disease (NAFLD).
(1,2) Paradoxically, deficiency or antagonism of intestinal FXR was shown to improve obesity, insulin resistance, and NAFLD, (5, 6) while activation of intestinal FXR by intestine-restricted fexaramine (FEX) also improves metabolic disorders in mice. (7) Thus, the role and mechanism of intestinal FXR in the regulation of lipid and glucose metabolism and NAFLD are controversial, are not completely understood, and require further study.
TGR5 is a Gas protein-coupled receptor activated by the secondary bile acids taurolithocholic acid (TLCA; EC50 5 0.3 lM) and DCA (EC50 5 1 lM). TGR5 is widely expressed in the epithelial cells of the gastrointestinal system, including intestine and gallbladder, and the hepatic sinusoidal endothelial cells and Kupffer cells but is not expressed in hepatocytes. (8) (9) (10) In the gastrointestinal tract, activation of TGR5 by bile acids and synthetic agonists protects intestinal barrier function, reduces inflammation, and stimulates gallbladder refilling and glucagon-like peptide-1 (GLP-1) secretion from enteroendocrine L cells. (11) GLP-1 stimulates insulin synthesis, increases postprandial insulin secretion from pancreatic b cells, and improves insulin resistance. (12) GLP-1 secretion is stimulated by nutrients in the intestinal lumen, such as carbohydrates, fats, and proteins; and glucose-induced GLP-1 secretion is enhanced by bile acids. (13) Activation of TGR5 increases intracellular cAMP to stimulate cAMPdependent protein kinase A, which activates cAMP response element binding protein and induces thyroid hormone deiodinase 2 (Dio2) and other browning factors, stimulating energy metabolism in white adipose tissue (WAT) and alleviating obesity and hepatic steatosis in diet-induced obese mice. (14, 15) Recently, TGR5 was found to have a key role in bile acid synthesis and fasting-induced hepatic steatosis in mice, (16) and activation of FXR induces TGR5 expression and GLP-1 secretion, improving insulin and glucose sensitivity and symptoms of metabolic disorder. (17) The gut-to-liver axis plays a critical role in the regulation of bile acid metabolism, bile acid pool size, and enterohepatic circulation of bile acids. Bile acids shape the gut microbiome to regulate host metabolism. (18) In this study, the effects of the intestine-restricted FXR agonist FEX on hepatic bile acid metabolism and the gut microbiota were examined, with the aim of unveiling the mechanism of TGR5/GLP-1 signaling in improving glucose and lipid metabolism. The data suggest that FEX treatment induced gut bacteria that produce LCA to activate TGR5/GLP-1 signaling, thereby improving insulin sensitivity and promoting adipose tissue browning. Thus, activation of TGR5/ GLP-1 signaling through modulation of the gut microbiota may have therapeutic potential for treating NAFLD, diabetes, and obesity.
Materials and Methods

MICE
Male wild-type C57BL/6J and leptin receptor-deficient diabetic mice Lepr db/db (db/db) were purchased from the Jackson Laboratory (Bar Harbor, ME). Fxr 2/ 2 mice (19) and Tgr5 2/2 mice (20) are on the C57BL/6J genetic background and were maintained in an Association for Assessment and Accreditation of Laboratory Animal Care-certified animal facility at Northeast Ohio Medical University. The Institutional Animal Care and Use Committee of Northeast Ohio Medical University approved all animal protocols. Mice were 12-16 weeks old at the time of study, maintained on a standard chow diet and water ad libitum, and housed in a room with a 12-hour light (6 AM to 6 PM) and 12-hour dark (6 PM to 6 AM) cycle.
GUT MICROBIOTA ANALYSIS Bacterial Isolation and Creation of the 16S Amplicons
Cecal contents (100 mg) were used for bacterial DNA extraction with an E.Z.N.A. isolation kit (Omega Biotek, Norcross, GA) according to the instructions provided. The extracted DNA concentration was measured using a Nanodrop, and samples were diluted to 10 ng/lL. DNA was then mixed with V4/V4 primers (515F, TCGTCGGCAGCGTCAG ATGTGTATAAGAGACAGGTGCCAGCMGCC G CGGTAA and 806R, GTCTCGTGGGCTCGG AGATGTGTATAAGAGACAGGGACTACHVG GGTWTCTAAT) and the Invitrogen Platinum SuperFi enzyme kit (ThermoFisher Scientific, Waltham, MA) for PCR amplification (988C, 2 minutes; 988C, 10 seconds, 56.58C, 20 seconds; 728C, 15 seconds for 20 cycles; 728C, 5 minutes). Products were run on a 1 3 agarose gel, verifying a 350-bp product.
Sequencing and Analysis
PCR products were sent to the Pennsylvania State University Genomics Core Facility for Illumina Miseq sequencing (150 3 150 paired end). Sequence files were analyzed using the Mothur software pipeline. (21) Reads were trimmed at 320 bp and aligned to the SILVA database. Chimeras were removed using UChime, (22) and reads were classified at a 75% cutoff using the ribosomal database project's training set. The summary file was used for further taxonomic analysis. Further sequence analysis was done by converting the trimmed fasta file into a distance file and aligning it to a phylogenic tree. This tree file was compared to an operational taxonomic unit file for generalized UniFrac analysis. (23) Significantly different genera were discovered using a Student t test, and the normalized values were converted into Z scores (Zi5 , and db/db mice were treated by oral gavage with the intestinespecific FXR agonist FEX (7) (50 mg/kg; BioVision, Inc., Milpitas, CA), once a day for 7-9 days. FEX is highly insoluble and was first dissolved in dimethyl sulfoxide (DMSO) and then diluted to 0.2% DMSO with phosphate-buffered saline (PBS). (14) For the GLP-1 secretion assay, mice (wild-type, Fxr 2/2 , Tgr5 2/2 , and db/db) were treated with FEX by oral gavage once a day for 6 days. On the seventh day, mice were fasted for 10 hours and gavaged with the dipeptidyl peptidase 4 inhibitor sitagliptin (3 mg/kg) and a liquid diet (Ensure Plus; 10 mL/kg, 1.5 calories/mL; 15% protein, 57% carbohydrate, and 28% fat) to stimulate GLP-1 secretion, as described. (24) Blood samples were collected immediately (time 0) and at 15 minutes, 30 minutes, and 60 minutes after liquid diet gavage. Serum GLP-1 levels were assayed using a GLP-1 (7-37) enzyme-linked immunosorbent assay kit (Millipore, Billerica, MA).
BILE ACID ANALYSIS
For bile acid quantitation in serum, ileum, colon, and gallbladder, d5-TCA at 1 lM was used as an internal standard. Samples were prepared by acetonitrile precipitation, and the supernatants were further diluted with 0.1% formic acid. Bile acid concentrations were determined by an ultra-high-performance liquid chromatography Synapt G2-Si quadruple time-of-flight mass spectrometry system (Waters Corp., Milford, MA) with an electrospray ionization source. Chromatographic separation was archived on an Acquity BEH C18 column (100 3 2.1 mm inner diameter, 1.7 lm; Waters Corp.). The mobile phase consisted of a mixture of 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile (B). Gradient elution was applied. The column temperature was maintained at 458C, and the flow rate was 0.4 mL/min. Mass spectrometric detection was operated in negative mode. A mass range of m/z 50-850 was acquired. All bile acid standards were purchased from Sigma-Aldrich (St. Louis, MO) or Toronto Research Chemicals (Toronto, ON, Canada).
ANTIBIOTIC TREATMENT
C57BL/6J wild-type mice (n 5 20) and db/db mice were provided a mixture of antibiotics (ABX) containing ampicillin (1 g/L; Sigma-Aldrich), vancomycin (500 mg/ L; Abbott Labs, Chicago, IL), neomycin sulfate (1 g/L; Pharmacia/Upjohn), and metronidazole (1 g/L; Sidmak Labs, Gujarat, India) in drinking water for 30 days. Antibiotic water was replaced every other day. During the last week mice were treated with FEX (50 mg/kg, n 5 10) or vehicle (0.2% DMSO in PBS, n 5 10) by oral gavage for 7-10 days. On the eighth day, mice (n 5 5) were used for GLP-1 secretion or an oral glucose tolerance test. Mice were fasted 6 hours and euthanized.
STATISTICAL ANALYSIS
All experimental data are presented as mean 6 standard error. Statistical analysis was performed by Student t test for analysis of two variants. P < 0.05 was considered statistically significant.
For further information on oral glucose and insulin tolerance tests, immunoblot analysis, bile acid pool size, and quantitative real-time PCR assays, see the Supporting Information.
Results
THE INTESTINE-RESTRICTED FXR AGONIST FEX STIMULATED GLP-1 SECRETION AND HEPATIC INSULIN SENSITIVITY
The effects of the intestine-restricted FXR agonist FEX on glucose-stimulated GLP-1 secretion were examined. Oral gavage of FEX stimulated GLP-1 secretion in wild-type C57BL/6J mice but not in Tgr5 2/2 or Fxr 2/2 mice, indicating that both FXR and TGR5 are involved in bile acid-stimulated GLP-1 secretion (Fig. 1A) . FEX treatment significantly improved oral glucose tolerance but not insulin tolerance (Fig. 1B) and significantly increased serum FGF21 levels (Fig. 1C) . Immunoblot analysis of liver extracts demonstrated that FEX treatment increased the ratios of phosphorylated AKT to total AKT and phosphorylated acetyl coenzyme A-carboxylase (ACC) to total ACC, indicating increased hepatic insulin sensitivity (Fig. 1D ). ACC is a key enzyme in lipogenesis, and phosphorylation inactivates ACC enzyme activity. Hematoxylin and eosin staining of inguinal WAT (iWAT) and epididymal WAT (eWAT) and uncoupling protein-1 (UCP-1) antibody staining of iWAT show beiging of WAT in FEX-treated mice compared to vehicle control mice (Supporting Fig. S1 ). FEX treatment increased mRNA expression of the adipose tissue browning factors Dio2, Ucp-1, peroxisome proliferator-activated receptor-c coactivator-1a, and PR domain containing-16 (Prdm16) in eWAT of wildtype mice (Fig. 1E) . Prdm16 transcription factor induces brown-like adipocytes (beige) in WAT and is required for brown adipose identity and function. (25, 26) FEX treatment did not induce browning factors in Fxr 2/2 and Tgr5 2/2 mice (Fig. 1E) . FEX treatment significantly induced ileum FXR target genes, including Tgr5, small heterodimer partner (Shp), Fgf15, organic solute transporter 1a (Osta) and Ostb mRNA levels (Fig. 1F) . In contrast to reducing the bile acid pool size as seen with the FXR-selective agonist obeticholic acid and the FXR and TGR5 dual agonist INT-767, (17) FEX treatment did not significantly alter bile acid content in the intestine, gallbladder, or liver or the total bile acid pool size (Fig. 1G) . Overall, these data suggest that FEX activation of both FXR and TGR5 stimulated glucose-dependent GLP-1 secretion from intestinal L cells to promote adipose tissue browning and increase glucose tolerance and hepatic insulin sensitivity.
FEX DID NOT AFFECT LIVER METABOLISM
In wild-type mice, FEX treatment did not affect serum or hepatic cholesterol and triglyceride levels (Supporting Fig. S2A) . Expression of the bile acid synthesis genes Cyp7a1, Cyp8b1, Cyp27a1, and oxysterol 7a-hydroxylase (Cyp7b1) mRNA and their respective proteins and of the FXR targets Shp and bile salt export pump mRNA levels was unchanged in liver (Supporting Fig. S2B ). Also unaltered were mRNA levels encoded by genes involved in fatty acid synthesis, fatty acid oxidation, triglyceride synthesis and hydrolysis, and lipoprotein metabolism (Supporting Fig.  S2C ). These data are consistent with FEX being an intestine-restricted FXR agonist, which is not absorbed and thus does not affect FXR target genes involved in bile acid synthesis and transport in the liver.
FEX TREATMENT INCREASED LCA CONTENT AND BILE ACID HYDROPHOBICITY IN GALLBLADDER AND INTESTINAL BILE
A previous study reported that FEX treatment increased LCA in mouse serum. (7) The serum bile acid concentration is very low and does not contribute to the total bile acid pool. Bile acid composition in gallbladder bile best represents the bile acids synthesized in the liver and circulated in the pool. FEX significantly altered bile acid composition in the gallbladder by increasing TLCA concentration by 1,000-fold and significantly increasing T-b-MCA, and decreasing tauro-a-MCA (T-c-MCA) and taurodeoxycholic acid (TDCA) but not TCA concentration ( Fig. 2A) . However, when plotted as a percentage of bile acid in bile, TCA was reduced because of a drastic increase of the percentage of TCA (Supporting Fig. S2D ). This change resulted in increased bile acid concentration and increased the hydrophobicity index of the bile ( Fig. 2A) . In the ileum, FEX treatment markedly reduced bile acid content and only LCA was significantly increased (Fig. 2B) . In the colon, FEX treatment markedly increased total bile acid content, increased DCA content to 90% of total bile acids, and increased LCA but decreased x-MCA (Fig. 2C) . In serum, FEX treatment markedly increased UDCA and TLCA, which became the predominant bile acids (45% each) (Fig. 2D) .
FEX INCREASED LCA SYNTHESIS AND ALTERED BILE ACID COMPOSITION
To investigate the mechanism of FEX induction of LCA, 16S ribosomal RNA sequencing analysis was performed on the gut microbiome from FEX-treated mice. Generalized UniFrac analysis showed a clear separation of the gut microbiome in FEX-treated versus vehicle control mice (Fig. 3A) . A heatmap displaying the Z score distribution of significantly different genera revealed that FEX increased the abundance of Helicobacter, Alistipes, Bacteroides, Anaeroplasma, Flavonifractor, Acetatifactor, and Shewanella (Fig. 3B) . Figure  3B also illustrates that FEX reduced the abundance of Clostridium sensu stricto, Turicibacter, Prevolella, unclassified Desulfovibrionaceae, unclassified Prevotellaceae, Barnesiella, and unclassified Turicibacter compared to vehicle control mice. Acetatifactor was recently identified as a bile acid-induced anaerobic bacteria most closely related to Clostridium cluster XIV. (27) A quantitative increase of Acetatifactor and Bacteroides was noted in FEX-treated mice compared to vehicle-treated control mice (Fig. 3C) . Bacteroides are the predominant bacteria in the gut capable of converting CDCA to LCA by 7a-dehydroxylase activity and UDCA to LCA by 7b-dehydroxylase activity. (28, 29) BSH activity in Clostridium deconjugates TCDCA to CDCA, which is converted to LCA by bacteria 7a-dehydroxylase. CDCA can be isomerized to UDCA, which can be converted to LCA by 7b-dehydroxylase activity in these bacteria (Fig. 3D) .
ABX REVERSED THE METABOLIC EFFECTS OF FEX
Because FEX treatment altered the gut microbiota and increased LCA-producing bacteria, we then treated mice with ABX to test whether they would reduce TLCA and prevent the FEX-induced metabolic phenotype changes. Mice were given a mixture of ABX containing ampicillin (1 g/L), vancomycin (500 mg/L), neomycin sulfate (1 g/L), and metronidazole (1 g/L) in drinking water for 4 weeks, followed by oral gavage of FEX during the last week of ABX treatment (Supporting Fig. S4A ). ABX did not affect serum aspartate aminotransferase and alanine aminotransferase levels (Supporting Fig. S4B ) but significantly reduced weight (Supporting Fig. S4C ).
ABX treatment completely prevented FEX-induced GLP-1 secretion (Fig. 4A, left) , did not improve glucose tolerance (Fig. 4A, middle) , and did not significantly change serum FGF21 levels (Fig. 4A, right) . Interestingly, FEX treatment significantly reduced the bile acid pool size in mice treated with ABX compared to vehicle control (Fig. 4B) , in contrast to a lack of effect in mice without ABX treatment (see Fig. 2E) . Surprisingly, FEX treatment reduced mRNA expression levels of the FXR targets Cyp7a1, Cyp7b1, and Results are expressed as mean 6 standard error. *Statistically significant difference (P 0.05) between treated and vehicle control; **statistically significant difference between treated and vehicle control (P 0.01). The Student t test was used for statistical analysis.
FIG. 3.
Gut microbiota analysis. Gut microbes were extracted according to the described methods after FEX treatment. FEX significantly altered the composition of the gut microbiota. (A) Generalized UniFrac analysis of the whole gut microbiota population between vehicle-treated and FEX-treated mice. Generalized UniFrac combines weighted and unweighted UniFrac analysis to incorporate both abundant and rare taxonomies, respectively. Significance was obtained using the R package Adonis, which is a permutational multivariate analysis of variance that is designed for distance matrices. (B) Effect of FEX on the genera of the gut microbiome. Z scores are used to illustrate significantly different genera (P 0.05) between vehicle-treated and FEX-treated mice. Samples were allowed to cluster under the R package heatmap.2's hclust function. The dendrogram shows related samples. (C) Two genera, Acetatifactor and Bacteroides, were shown to increase after FEX treatment. (D) Gut bacteria induce LCA production to stimulate TGR5 signaling. BSH deconjugates TCDCA to CDCA, which is converted to LCA by bacterial 7a-dehydroxylase. CDCA can be epimerized to UDCA, which is converted to LCA by bacterial 7b-dehydroxylase. LCA activates TGR5 in the intestine. *Statistically significant difference (P 0.05) between treated and vehicle control. Shp in the liver of ABX-treated mice (Fig. 4C ), while expression of these genes was unaffected without ABX treatment. This may be due to increased Fgf15 production (Fig. 4D) . Consistent with changes in mRNA levels, immunoblot analysis showed a decrease in CYP7A1 and CYP8B1 proteins in FEX-treated mouse liver (Fig. 4C, right panel) . In the ileum of ABX-treated mice, FEX induced mRNA encoding Tgr5, Shp, Osta, and Ostb, and prohormone convertase 1/3 (Pc1/3), which processes preproglucagon to GLP-1 (Fig. 4D) . Interestingly, induction of intestinal FXR target genes by FEX was doubled in ABX-treated mice compared to mice without ABX treatment (see Fig. 1F ). FEX also did not induce expression of WAT browning factors in inguinal WAT (iWAT) tissues of ABX-treated mice (Fig. 4E) . ABX treatment reduced bile acid hydrophobicity, completely abolished LCA and TLCA, and increased Ta-MCA and Tb-MCA, which became the predominant bile acids (>90% total bile acids) in mouse gallbladder bile (Fig. 4F , compared to vehicle control, Fig.  2A ). FEX treatment did not alter the bile acid composition or the bile acid hydrophobicity index in ABXtreated mice (Fig. 4F) . ABX completely altered serum bile acid composition, abolished UDCA and TLCA, and increased Tb-MCA, which became the predominant bile acid in the serum (Fig. 4G, compare to Fig.  2D ). FEX did not alter serum bile acid composition in ABX-treated mice (Fig. 4G) . These data support the finding that the metabolic effects of FEX depend on gut microbiota composition.
FEX-INDUCED BILE ACID SULFOTRANSFERASE GENE EXPRESSION IN THE INTESTINE
LCA is a potent pregnane X receptor agonist, which induces CYP3A4 (or mouse Cyp3a11) to metabolize LCA and induce the bile acid-specific sulfotransferase 2 (Sult2) family to conjugate sulfur to LCA for renal and fecal excretion. (30, 31) The liver of FEX-treated mice appears normal despite high levels of LCA. Thus, the effect of FEX treatment on Sult expression in liver and intestine was examined. Interestingly, FEX strongly induced liver-specific and male-predominant Sult2a8 mRNA (32) and female-specific Sult2a1 mRNA in liver, ileum, and colon of wild-type mice (Supporting Fig. S3A ), while FEX induced Sult2a2 mRNA in ileum and colon and Sult2a3 mRNA in colon only (Supporting Fig. S3A ). FEX also induced Sult2a1, Sult2a2, and Sult2a8 mRNA in Fxr 2/2 and Tgr5 2/2 mice, indicating that FEX induction of Sults is independent of FXR and TGR5 (Supporting Fig.  S3B ). ABX treatment reversed FEX induction of Sult2a1, Sult2a2, and Sult2a3 in the ileum (Supporting Fig. S3C ). These data suggest that in mice the increase in LCA by FEX induces Sults to detoxify LCA, thus protecting mice from LCA toxicity.
FEX IMPROVED GLUCOSE TOLERANCE IN Lepr db/db MICE
To test if activation of intestinal FXR improves insulin sensitivity and glucose metabolism, leptin receptor-deficient and diabetic db/db mice were gavaged with FEX. FEX treatment significantly reduced the fat mass to body weight ratio but did not change the lean mass to body weight ratio in db/db mice compared to wild-type mice (Fig. 5A) . FEX treatment significantly decreased serum cholesterol and free fatty acids, but not triglyceride levels, and decreased hepatic triglycerides and free fatty acids (Fig. 5B) . FEX treatment stimulated serum GLP-1 levels by 2-fold compared to vehicle-treated db/db mice (Fig. 5C ). Oral glucose and insulin tolerance tests demonstrate that FEX treatment significantly improved glucose tolerance (Fig. 5D ) and insulin tolerance (Fig. 5E ) in db/db mice. FEX treatment also significantly increased the phosphorylated AKT 473 /AKT and phosphorylated ACC-1/ACC-1 ratios in the liver, indicating improved insulin signaling (Fig. 5F ).
FEX treatment significantly increased liver FXR targets Shp, Fgf15, OSTa/b, and Pc1/3 mRNAs but not Asbt or Gcg mRNA expression in db/db mice compared to wild-type mice (Fig. 6A, left) . Furthermore, FEX treatment suppressed Pepck and G6pase mRNA in db/db mice (Fig. 6A, middle) . The db/db mice had a 2-fold higher serum FGF21 concentration compared to wild-type mice (see Fig. 1C ), and FEX treatment did not significantly alter serum FGF21 levels in db/db mice (Fig. 6A, right) . FEX treatment induced Dio2, Ucp1, and Ppargc-1a in brown adipose tissue (Fig. 6B) . FEX induced Prdm16 in subcutaneous WAT and eWAT, and Prdm16 and Ucp-1 in iWAT (Fig. 6C) . Immunoblot analysis showed that FEX induced UCP-1 protein in iWAT (Fig. 6D ). Hematoxylin and eosin staining showed that FEX treatment caused beiging of iWAT and eWAT (Supporting Fig. S5A ) but did not alter liver gene expression in db/db mice (Supporting Fig. S5B ). Thus, FEX treatment improved glucose and lipid metabolism, insulin sensitivity, and WAT browning (beiging) in db/db mice.
ABX TREATMENT REVERSED THE BENEFICIAL METABOLIC EFFECTS OF FEX IN db/db MICE
To determine if ABX treatment would prevent FEX-induced metabolic benefits in db/db mice, we treated db/db mice with ABX for 4 weeks and in the last week gavaged FEX. FEX did not affect serum and liver cholesterol and triglyceride levels (Supporting Fig.  S6A ) or serum FGF21 (Supporting Fig. S6B ). FEX had no effect on glucose-induced GLP-1 secretion (Supporting Fig. S6C ), glucose tolerance (Supporting Fig. S6D ), or insulin tolerance (Supporting Fig. S6E ). However, FEX still induced FXR target genes Shp and Fgf15, but not Ost or Pc1/3, in ABX-treated db/db mice (Supporting Fig. S6F ). FEX did not affect adipose tissue browning factors in iWAT (Supporting Fig. S6G ) or liver bile acid or lipogenesis gene mRNA expression (Supporting Fig. S6D ). Overall, ABX treatment completely reversed the beneficial metabolic effects of FEX in db/db mice.
Discussion
Activation of intestinal FXR signaling was shown to protect against NAFLD, (7) but deficiency of intestinal FXR was also shown to prevent diet-induced obesity, diabetes, and NAFLD. (5, 6) Different mechanisms may be involved in the paradoxical effects of intestinal FXR signaling on obesity and diabetes.
Results from this study demonstrate that the intestine-restricted FXR agonist FEX modulates the gut microbiota to induce Acetatifactor and Bacteroides, both of which have high BSH and 7a-dehydroxylase and 7b-dehydroxylase activity to produce LCA from CDCA and UDCA. LCA then activates TGR5 signaling to stimulate GLP-1 secretion from L cells, resulting in the promotion of adipose tissue browning and improvement of hepatic insulin signaling and glucose metabolism. Acetatifactor belongs to the Clostridium cluster XIV and is most closely related to the genera Anaerostipes, Blautia, Clostridium, and Ruminococcus. (27) Acetatifactor grows under strictly anoxic conditions and produces acetate and butyrate. Clostridium and Bacteroides are grampositive anaerobic bacteria in the gut with high BSH activity for deconjugation of TCDCA and tauro-UDCA (TUDCA) to CDCA and UDCA, which are converted to LCA by 7a-dehydroxylase and 7b-dehydroxylase, respectively. (28, 29, 33) FEX treatment improved lipid profiles, GLP-1 secretion, insulin and glucose tolerance, and WAT browning in db/db mice; and ABX treatment completely reversed the beneficial metabolic effects of FEX in db/db mice. Interestingly, FEX induction of intestinal Shp and Fgf15 mRNA in ABX-treated mice was significantly higher in wild-type mice without ABX treatment but not in db/db mice without ABX treatment. This may be because gut microbiota blunts FEX efficacy and ABX treatment restored FEX efficacy to increase FGF15 and reduce Cyp7a1 and Cyp8b1 expression and bile acid pool size. FEX is an intestinerestricted FXR agonist and is not absorbed into the intestine or the blood circulation. FGF15, FGF21, and GLP-1 all have been shown to improve hepatic metabolism and adipose tissue energy metabolism. (15, 34, 35) An interesting question arises regarding the mechanism by which FEX regulates hepatic metabolism, glucose sensitivity, and adipose browning. It has been reported that the effects of FGF21 in WAT browning are independent of UCP-1.
(36) The current study demonstrates that ABX treatment abolished the FEX induction of GLP-1 and adipose tissue browning and increased intestinal FGF15 production, suggesting that FGF15 was not involved in the WAT browning induced by FEX. Thus, TGR5/GLP-1 signaling may play a major role in FEX-induced adipocyte browning and improving hepatic glucose and insulin sensitivity in db/db mice.
Supporting Fig. S7 illustrates that FXR and TGR5 are coexpressed in intestinal L cells. (17) FEX activation of intestinal FXR shaped the gut microbiota to induce Acetatifactor and Bacteroides to convert TCDCA to LCA, which activates TGR5 to stimulate GLP-1 secretion from L cells, ultimately improving liver function and insulin and glucose tolerance. LCA also activates TGR5/cAMP signaling to induce WAT browning and energy metabolism to reduce weight. Free fatty acids released from adipose tissues activate peroxisome proliferator-activated receptor-gamma (PPARc) in adipose tissue and PPARa in hepatocytes to induce FGF21, which activates PGC-1a to stimulate energy metabolism and enhance insulin sensitivity in diabetes. (34) The hepatic FXR/SHP pathway is not activated by FEX treatment. FGF21 antagonizes FGF15/ FGFR4 signaling (37) and results in no effect on CYP7A1 expression and bile acid synthesis in FEXtreated mice.
Germ-free mice, ABX-treated mice, and Cyp8b1
2/2
mice all have increased bile acid pool size and Tb-MCA and are resistant to diet-induced hepatic steatosis. (38, 39) Intestine-specific Fxr-null mice, Gly-MCA antagonism of intestinal FXR activity and the antioxidant tempol all show beneficial effects in reducing weight and improving hepatic steatosis. However, the underlying mechanisms for improved metabolic phenotypes may be different in these mouse models. Intestinal FXR agonists or antagonists may shape the gut microbiota differently to regulate host metabolism and could explain the reported paradoxical effects of intestinal FXR in obesity and diabetes. Gly-MCA decreases the ratio of Firmicutes to Bacteroidetes and inhibits BSH activity, and the potent FXR agonist GW4064 reversed Gly-MCA-induced changes of metabolic phenotypes and the gut microbiome. (40) Tempol alters the gut microbiome by reducing Lactobacillus and its BSH activity, leading to increase in Tb-MCA. (41) In conclusion, this study uncovered a mechanism whereby activation of intestinal FXR altered bile acid metabolism by increasing LCA-producing bacteria in the gut. The elevated LCA levels activate intestinal TGR5, which then stimulates GLP-1 secretion from intestinal L cells to improve hepatic glucose and lipid metabolism and induces adipose tissue browning. Interestingly, a recent study reported that C57BL/6J mice reconstituted with Bacteroides acidifaciens had increased serum insulin and GLP-1 and decreased dipeptidyl peptidase-4, (42) suggesting that B. acidifaciens may prevent obesity and improve insulin sensitivity in mice and supporting the view that the gut microbiota can be reshaped to stimulate TGR5/GLP-1 signaling to reduce weight and improve liver metabolism. The intestinal FXR-gut microbiota-TGR5-GLP-1 axis plays a critical role in mediating intestinal bile acid receptor signaling to regulate liver metabolism and homeostasis. Activation of TGR5/GLP-1 signaling through modulation of the gut microbiota may have therapeutic potential for treating NAFLD, diabetes, and obesity.
